Nanobiotix annonce son plan d’enregistrement clinique dans les cancers de la Tête et du Cou avec NBTXR3 aux Etats-Unis à la suite du retour de la FDA Préparation d’une étude clinique évènementielle, randomisée et évaluant la survie globale (SG) aux États-UnisLe retour (pre-IND) de la Food and Drug Administration (FDA) permet de clarifier l’approche...

Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback Moving forward with Overall Survival (OS)-based, randomized, event-driven clinical trial for the United StatesPre-IND feedback from US Food and Drug Administration (FDA) provides clarity to...

PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...

SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...